WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ: RGEN) today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%. Bioprocessing product revenue is anticipated to be $15.0 million, a 45% increase over the prior year and royalty and other revenue is anticipated to be about $12.3 million, an increase of 16% from the prior year. Research and development expenses are expected to be between $12.5-$13.0 million, compared to $14.2 million last fiscal year. Selling, general and administrative expenses are expected to be between $8.0-$8.5 million, compared to $7.1 million in fiscal year 2010. Net income for the year is expected to be between $0.0-$0.5 million and cash and investments as of March 31, 2011 are expected to be $61.5 million.
